Careers  |  Sign In  |  Register

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the assessment of checkpoint inhibition in melanoma. During the OpACIN study, none of the patients with an initial response relapsed. As neoadjuvant therapy is a good prognostic indicator for long-term outcome, Dr. Blank is hopeful the FDA will accelerate the approval process to grant patients earlier access.

Learn more by clicking here.